Pregnancy outcomes among women with inherited thrombophilia polymorphisms

Article

Asymptomatic, nulliparous, heterozygous carriers of the prothrombin gene mutation are 3.6 times as likely as women who do not carry the mutation to experience severe pregnancy complications.

Asymptomatic, nulliparous, heterozygous carriers of the prothrombin gene mutation are 3.6 times as likely as women who do not carry the mutation to experience severe pregnancy complications, including severe preeclampsia, fetal growth restriction less than the fifth percentile for sex and gestation, stillbirth, and neonatal death, according to a prospective cohort study conducted in Australia.

The authors of the study, which involved 1,707 women, found particularly strong associations between heterozygosity for prothrombin gene mutation and placental abruption (odds ratio [OR], 12.15; 95% confidence interval [CI], 2.45-60.39) and between homozygosity or heterozygosity for factor V Leiden and stillbirth (OR, 8.85; 95% CI, 1.60-48.92), although the latter finding involved a very small number of patients (n=6).

They also found that homozygosity for the methylenetetrahydrofolate reductase enzyme (MTHFR) A1298C polymorphism may actually be protective against such adverse pregnancy outcomes, particularly severe fetal growth restriction.

Recent Videos
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Ivie Odiase, MD
Susan Khalil, MD
Sharon Erdrich, PhD, discusses why oral health should be routine in health care | Image Credit: linkedIn.com.
Sharon Erdrich, PhD, highlights oral health's impact on chronic pain | Image Credit: linkedIn.com.
Fiona Gilbert, MA, MB, discusses breast cancer screening for dense breasts | Image Credit: newn.cam.ac.uk
Related Content
© 2025 MJH Life Sciences

All rights reserved.